Cell Therapies and Immunotherapy Conference

October 20-22, 2019
Add to Calendar

The Cell Therapies and Immunology conference will offer a chance for scientists, engineers and clinicians working with T-Cell immunotherapy to showcase new discoveries and developments in the field. This two day conference will address challenges and discoveries in the cell therapy and immunotherapy fields that will ultimately change the future of healthcare.

Abstract Deadline: Sunday, September 1, 2019

Submit an AbstractRegister Here

Invited Speakers:

Session Topics:

  1. Update From the Frontline: CARs in the Clinic Disease specific differences in outcomes and safety, real-world experience with CD28 vs. 4-1BB, solid vs heme
  2. Mechanisms of Relapse and Strategies to Overcome Antigen escape, tumor heterogeneity, T cell quality and persistence
  3. Beyond Conventional CARs - Alternative CAR architectures, split CARs, TCRs, combination therapies
  4. Gene Editing in Cell Therapy Applications of editing, novel technologies, regulatory considerations for gene edited products
  5. Moving Beyond Autologous T cells: Allogeneic and Other Cell TypesAllogeneic approaches, gd T cells, NK cells, iPSC derived products
  6. Solid tumors: Increasing Specificity and Overcoming TME - Strategies to enhance tumor specificity, increase T cell trafficking, persistence, and potency
  7. Bigger, Stronger, Faster: Synthetic Biology Approaches to Develop more Potent Therapies - Building synthetic gene circuits, delivering therapeutic payloads, armored CARs
  8. Cell Therapy Applications Beyond Oncology - Using cells as therapeutics in autoimmune disease, CAR Tregs, etc.

Conference Chairs:

Organizing Committee:

  • Yvonne Chen, University of California, Los Angeles
  • Justin Eyquem, University of California, San Francisco
  • Lior Nissim, The Hebrew University-Hadassah Medical School
  • Barbra Sasu, Allogene Therapeutics
  • Navin Varadarajan, University of Houston 
  • Pin Wang, University of Southern California

Featured Speakers

Leonardo Ramos Ferreira

Cell-based gene therapies offer unprecedented promise for medicine. One day, it may be possible to cure degenerative diseases that consist of the loss of one or several specialized cell functions, as well as to decelerate the deterioration our bodies experience during aging. However, several hurdles must be surpassed in order to establish cell transplantation therapies, a major one being rejection by the recipient's immune system. This challenge is particularly prominent for autoimmune disorders, such as type 1 diabetes and multiple sclerosis, where the immune system mediates the...Read more

Mohamad Hamieh

Dr. Hamieh received his Ph.D. from Rouen University in France. Currently, he is a research associate in Dr. Michel Sadelain lab at Memorial Sloan Kettering Cancer Center in New York. His work focuses on understanding the dynamics of CAR T cell anti-tumor response. Recently, he described a new mechanism of antigen escape from CAR T cell therapy where T cells reduce target antigen density on tumor cells and T-cell activity via trogocytosis.Read more

Samira Kiani

Samira Kiani received her medical doctorate degree (M.D.) from Tehran University of Medical Sciences. Prior to joining ASU, she completed her postdoctoral training in the center for Synthetic Biology at Massachusetts Institute of Technology, where she worked on developing synthetic gene circuits to reprogram the function and behavior of mammalian cells based on the Clustered Regularly Interspaced short Palindromic Repeats (CRISPR)/Cas9 technology. Cas9 protein is a DNA cleaving enzyme that can be targeted to any DNA sequence by means of a small guide RNA (gRNA) and can be adapted both for gene editing and gene regulation.Read more

David Miklos

Dr. Miklos is the Clinical Director of Stanford University’s Center for Cancer Cell Therapy, and leads Stanford’s CAR therapy clinical trials for patients with aggressive lymphomas.

David is a seasoned hematopoietic cell transplant (HCT) clinician and immunologist with special interest in B cell biology, tumor immunology and graft versus host disease (GVHD). His Stanford laboratory has applied cutting edge technologies to human translational research including:  protein microarrays for antibody identification, antigen specific B cell identification, and next-generation deep...Read more

Lior Nissim

Dr. Lior Nissim is an Assistant Professor leading the synthetic biology group in the Hebrew University of Jerusalem School of Medicine. His lab develop synthetic biology platforms implemented as effective, practical solutions for therapeutics and to decipher human biology.

Lior received his B.Sc. at the Tel-Aviv University. His M.Sc.  comprised of basic cancer biology research in the lab of Prof. Varda Rotter, Department of Molecular Cell Biology, Weizmann Institute of Science. He then accomplished his Ph.D the multidisciplinary biophysics lab of Prof. Roy Bar-Ziv , Department...Read more

Hideho Okada, MD, PhD

As a physician–scientist, Dr. Okada has been dedicated to brain tumor immunology and development of effective immunotherapy for brain tumor patients for over 20 years. His team was one of very first to discover cytotoxic T lymphocyte (CTL) epitopes in glioma-associated and glioma-specific antigens. Dr. Okada also found critical roles for the integrin receptor very late activation antigen (VLA)-4 and the chemokine CXCL10 in facilitating entry of CTLs to the brain tumor site. Dr. Okada has translated these discoveries into a number of innovative immunotherapy clinical studies in both adult...Read more

Samuel Rabkin

Samuel Rabkin is the Thomas A. Pappas Professor in Neurosciences and Professor of Neurosurgery (Microbiology) at Harvard Medical School, Boston MA, and Virologist in Neurosurgery in the Brain Tumor Research Center at Massachusetts General Hospital, Boston.  Dr. Rabkin's lab has focused on the development of oncolytic herpes simplex virus (oHSV) for cancer therapy, including the first oHSV to enter clinical trial in the US and oHSV immunovirotherapy strategies and combinations for glioblastoma.  ...Read more

Anjana Rao

Dr. Anjana Rao obtained her Ph.D. in Biophysics from Harvard University and was a Professor at Harvard Medical School until 2011, when she moved to the La Jolla Institute and UCSD (University of California in San Diego). Her research is focused on the regulation of gene expression, using immune cells, haematopoietic stem cells and embryonic stem cells as model systems. Her lab purified and molecularly characterized the calcium/ calcineurin-regulated transcription factor NFAT; defined diverse transcriptional programs regulated by NFAT proteins in T cells; identified the pore subunit of the...Read more

Eliana Ruggiero

 Dr. Eliana Ruggiero received her Ph.D. in Biology from the University of Heidelberg “Ruprecht-Karls-Universität Heidelberg” (Germany) in 2013, trained at the laboratory of Christof von Kalle. She focused her research on the exploitation of sequencing technologies for the characterization of the T cell receptor (TCR) repertoire. She studied the distortions in the immune repertoire occurring upon infections and in tumors, with particular focus on the overtime clonal tracking of individual clonotypes. In 2015, she joined Chiara Bonini’s lab at San Raffaele Scientific Institute in Milan...Read more

Pamela Skinner

Dr. Skinner is a Professor in the Department of Veterinary and Biomedical Sciences at the University of Minnesota. Dr. Skinner’s HIV research program focuses on understanding disease immunopathogenesis and the development of novel immunotherapy treatments for HIV. Her HIV cure efforts are based on findings that B cell follicles are somewhat of an immune privileged site where low levels of virus-specific CTL allow ongoing HIV replication. She is presently working to develop a cellular immunotherapy which targets HIV-specific chimeric antigen receptor (CAR) T cells to B cell follicles to...Read more

Fyodor Urnov

Dr. Urnov is a pioneer in the field of genome editing, with a diverse background in academia, industry and the nonprofit sector. He joined the Innovative Genomics Institute (IGI) as Scientific Director of Technology and Translation in 2018. Before joining the IGI he served as the Associate Director of Altius Institutes for Biomedical Sciences. Prior, he was at Sangamo BioSciences from 2000 - 2016, where he co-developed and co-named human genome editing at native loci using engineered nucleases, and led the effort developing all major modalities of editing (correction, disruption, and...Read more

Lili Yang

Dr. Lili Yang received her Ph.D. degree in Biology from the California Institute of Technology (Caltech) in 2004, trained at the Laboratory of David Baltimore. She led the Engineering Immunity Program at Caltech from 2004 to 2012, developing immunotherapies for cancer and HIV/AIDS. She joined the University of California, Los Angeles (UCLA) as an Assistant Professor in 2013. Her laboratory at UCLA studies tumor immunology and cancer immunotherapy, with a special focus on stem cell-based and gene-engineered immunotherapy for cancer. Her work resulted in 29 publications, 10 patents, and 2...Read more